Phase 1/2 Multi-Center Open-Label Study to Evaluate the Safety Tolerability and Preliminary Anti-tumor Activity of TNG462 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Solid Tumors
  • Age: Between 18 Year(s) - 99 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Has confirmed histologic or cytologic diagnosis of a locally advanced, metastatic, and/or unresectable solid tumor
    2. Has documented homozygous deletion of MTAP in a tumor detected by a validated NGS test, or absence of MTAP protein in a tumor detected by a validated IHC test
    3. Must be willing to provide an on-treatment tumor biopsy

You may not be eligible for this study if the following are true:

    1. a known allergy, hypersensitivity, or intolerance to TNG462 or its excipients
    2. a diagnosis of primary CNS tumor
    3. are currently participating in or has planned concurrent participation in a study of another investigational agent or device



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.